Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Sciences announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

In August 2024, the FDA granted accelerated approval to seladelpar for the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA), in adults who have had ...

The increase was driven by higher demand for HBV and HDV drugs, along with incremental sales of Livdelzi (seladelpar) in primary biliary cholangitis (PBC). Veklury sales plunged 53% to $337 ...

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term ...

In December, we received a positive CHMP opinion for seladelpar and we're excited to potentially bring the first and only PBC treatment shown to significantly reduce alkaline phosphatase or ALP ...

Gilead will report the first full quarter sales from Livdelzi (seladelpar) after gaining FDA accelerated approval in mid-August 2024 for primary biliary cholangitis. In October, Gilead Sciences ...

With the FDA approval of Gilead's seladelpar, there have now been two in a matter of weeks. The US agency has cleared seladelpar under the Livdelzi brand name as a second-line therapy for PBC in ...